JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis

Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to r...

Full description

Bibliographic Details
Main Authors: Andrew T. Kuykendall, Rami S. Komrokji
Format: Article
Language:English
Published: Innovative Healthcare Institute 2021-08-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
jak inhibitor
myelofibrosis
myeloproliferative neoplasm
rare disease
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-20-36

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-20-36

Similar Items